Figure 2. Switching from bevacizumab to ranibizumab does not provide further improvements in visual acuity or macular thickness.

A: The mean logMAR visual acuity decreases after treatment with bevacizumab up to the crossover point shown by the arrow. After switching treatments to ranibizumab, no further change in logMAR visual acuity is seen; B: There is minimal change in central subfield thickness after treatment with bevacizumab. After switching to ranibizumab, there is some decrease in macular thickness, but it does not reach statistical significance. Mean±SEM.